slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 45,001-45,030
Pages 10,126
Rows per page 30
Component
45,001-45,030 of 303,780
18
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 2 hits
21
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 2 hits
27
The slide uses a three-column icon-based layout to summarize key IP milestones.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps2 hits
29
The slide combines a financial summary with a timeline of milestones and a value proposition for their lead asset.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps2 hits
07
The chart compares quarterly container volumes between 2022 and 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction2 hits
08
The chart compares 2022 vs 2023 quarterly container volumes.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction2 hits
09
The chart shows quarterly container volume (FEU) for 2022 vs 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction2 hits
01
Morgan Stanley | Investor Presentation Deck | 13 slidesMorgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What Is2 hits
13
Morgan Stanley | Investor Presentation Deck | 13 slidesMorgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · New Bliss2 hits
03
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Team2 hits
04
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle2 hits
15
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle2 hits
18
The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle2 hits
19
The slide uses three distinct chart types to demonstrate efficacy and metabolic impact.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle2 hits
24
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle2 hits
04
The slide uses a standard pharmaceutical pipeline visualization (Discovery to NDA).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 2 hits
09
The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution2 hits
11
Includes details on screen failures and co-treatment with Riluzole.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution2 hits
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution2 hits
17
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution2 hits
19
The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction2 hits
20
The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction2 hits
21
The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 2 hits
26
The slide outlines the RoAD study parameters including patient population, dosing, and primary/secondary endpoints.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 2 hits
31
The chart shows a clear divergence between the treatment and placebo arms over time, with a 29.2% difference at the 180-day mark.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 2 hits
32
The chart shows a divergence in SVC decline between the treatment and placebo groups over time.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 2 hits
16
The chart highlights NYCB's generally lower non-performing loan ratios compared to the broader market index over the observed period.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
17
The chart highlights a significant spike in charge-offs for the S&P index during the 2008-2012 period compared to NYCB.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
18
The chart uses a dashed line to represent the peer median of 0.55%.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
20
The slide highlights NYCB's relative capital position using two different metrics (Adjusted vs Reported).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits